Schwiebert, Erik et al. published their patent in 2016 |CAS: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.Electric Literature of 25813-24-5

On February 11, 2016, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.Electric Literature of 25813-24-5 The title of the patent was Coumarin derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin derivative compounds and methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).Electric Literature of 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.Electric Literature of 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Schwiebert, Erik et al. published their patent in 2014 |CAS: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.SDS of cas: 25813-24-5

On September 25, 2014, Schwiebert, Erik; Streiff, John; Dixon, John; Gao, Hongwu; Ritchie, Joseph P.; Seales, Eric C.; Mai, Deborah published a patent.SDS of cas: 25813-24-5 The title of the patent was Preparation of coumarin thiazolyl derivatives and methods of use in treating hyperproliferative diseases. And the patent contained the following:

Coumarin thiazolyl derivatives I [R1 is H, halogen, OH, (un)substituted alkoxyl, (un)substituted amino, (un)substituted C1-6-alkyl, (un)substituted heterocycloalkyl; R2 is H, halogen, OH, NO2, CN, N3, thiocyanato, CF3, (un)substituted alkoxyl, (un)substituted amino, (un)substituted carbonyl, or (un)substituted C1-6-alkyl; R3 is H or substituted or unsubstituted C1-6-alkyl; R4 is (un)substituted C1-6-alkyl, (un)substituted aryl or (un)substituted heteroaryl; X is S or O; and, Y is O, NH or NMe] are provided. Thus, DBM-308 (II) was prepared from 3-chlorosalicylaldehyde via cyclocondensation with Et acetoacetate in EtOH containing piperidine to give 3-acetyl-8-chlorocoumarin (III); regioselective bromination with CuBr2 in CHCl3 to give 3-(bromoacetyl)-8-chlorocoumarin (IV); and cyclocondensation with 2-MeOC6H4NHC(:S)NH2 to give II. Methods for the treatment of hyperproliferative diseases, such as cancer, polycystic kidney disease, and fibrosis of different tissues (e.g., idiopathic pulmonary fibrosis), are provided. The antiproliferative activity of II was determined [GI50 = 166 nM; TGI = 247 nM; LC50 = >4,000 nM; IC50 = 0.69 μM vs. N828 cell line (hyperproliferative PKD cells); IC50 = 0.54 μM vs. 3-8C1 cell line (hyperproliferative PKD cells)]. The methods include administering to a subject a compound as described herein. Also provided are methods for inhibiting the interaction between two or more heat shock protein chaperones in a cell. The experimental process involved the reaction of 3,5-Dibromo-4-methoxypyridine(cas: 25813-24-5).SDS of cas: 25813-24-5

The Article related to coumarin thiazolyl derivative preparation treatment hyperproliferative disease, cancer treatment coumarin thiazolyl derivative, polycystic kidney disease treatment coumarin thiazolyl derivative, tissue fibrosis treatment coumarin thiazolyl derivative, idiopathic pulmonary fibrosis treatment coumarin thiazolyl derivative and other aspects.SDS of cas: 25813-24-5

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Wang, Jian et al. published their research in Chemical Communications (Cambridge, United Kingdom) in 2007 |CAS: 75449-26-2

The Article related to aminobipyridine pyridylpyrimidine derivative preparation structure, crystal structure aminobipyridine pyridylpyrimidine cobalt quaterpyridine derivative complex, cobalt quaterpyridine derivative complex preparation structure, pyridinecarbaldehyde aminobipyridine schiff preparation rearrangement cobalt catalyzed mechanism and other aspects.Computed Properties of 75449-26-2

On September 21, 2007, Wang, Jian; Onions, Stuart; Pilkington, Melanie; Stoeckli-Evans, Helen; Halfpenny, Joan C.; Wallis, John D. published an article.Computed Properties of 75449-26-2 The title of the article was Metal catalyzed rearrangement of a 2,2′-bipyridine Schiff-base ligand to a quaterpyridine-type complex. And the article contained the following:

A Co(II) quaterpyridine-type complex, [Co(L2)(H2O)(CH3CN)](ClO4)2 (L2 = I), has been prepared via a one-pot transformation of a 2,2′-bipyridine Schiff base ligand (II) in the presence of a Lewis acidic metal salt. The mol. structure of the cobalt complex has been determined using X-ray crystallog. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Computed Properties of 75449-26-2

The Article related to aminobipyridine pyridylpyrimidine derivative preparation structure, crystal structure aminobipyridine pyridylpyrimidine cobalt quaterpyridine derivative complex, cobalt quaterpyridine derivative complex preparation structure, pyridinecarbaldehyde aminobipyridine schiff preparation rearrangement cobalt catalyzed mechanism and other aspects.Computed Properties of 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Stoessel, Philipp et al. published their patent in 2015 |CAS: 39919-70-5

The Article related to iridium cyclometalated arylpyridine arylquinoline arylisoquinoline arylbenzimidazole complex preparation electroluminescence, electroluminescent material iridium cyclometalated complex preparation luminescence oled manufacturing, bromination borylation suzuki buchwald coupling derivatization iridium cyclometalated complex and other aspects.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

On July 16, 2015, Stoessel, Philipp; Koenen, Nils published a patent.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine The title of the patent was Cyclometalated arylpyridine and arylbenzimidazolylidene metal complexes as electroluminescent materials for organic light-emitting devices. And the patent contained the following:

Cyclometalated iridium complexes [(Q1-Q2)3Ir] (1), [(Q1-Q2)2(Q3-Q4)Ir] (2) and [(Q1-Q2)2IrL] (3; for 1-3: Q1, Q3 = substituted pyridinyl-κN, quinolinyl-κN, isoquinolinyl-κN, benzimidazolylidene-κC2; Q2, Q4 = substituted aryl-κC2; L = acetylacetonato, dipivaloylmethanato), useful as triplet-emitting dopants for light-emitting layers of organic electroluminescent devices (OLEDs), featuring better solubility in organic solvents and enhanced stability, were prepared by conventional cyclometalation, ligand substitution and derivatization reactions and tested for performance and electrooptical characteristics by manufacturing test OLEDs according to standard protocols. The homoleptic complexes 1 were prepared by cyclometalation of the corresponding ligands Q1-Q2H with [Ir(acac)3], typically as fac-isomers. The heteroleptic tris-cyclometalated complexes 2 were prepared via cationic intermediates [(Q1-Q2)2Ir(HOMe)2][OTf] (4), which were results of halogen abstraction and methanolysis of iridium dimers [(Q1-Q2)4Ir2(μ-Cl)2] (5), by cyclometalation of the ligands Q3-Q4H with 4. The complexes of the type 3 were prepared by complexation of dimers 5 or methanol complexes 4 with the β-diketones HL. The ligands in the some of the complexes 1 or 2 were modified by bromination, borylation and coupling reaction sequence; the bromides [(Q1-Q2-Br)3Ir] (6) were arylated via Suzuki coupling with arylboronates or converted into aromatic amines [(Q1-Q2-NR2)3Ir] (R = aryl, or NR2 = substituted 9-carbazolyl) by Buchwald amination reaction with amines HNR2 or carbazoles. The bromides 6 were also used as comonomers in Suzuki polymerization of arene and carbazole dibromides with arylenediboronates, giving electroluminescent polyarylene-polycarbazoles containing up to 10% of [(Q1-Q2)3Ir] structural fragments. In an example, reaction of 10 mmol of Na[(acac)2IrCl2] with 40 mmol of the proligand, 2-(1,2,3,4-tetrahydro-1,4-ethano-6-naphthyl)pyridine (H-LB1) in the presence of 3-10 g of propylene glycol as solvent at reflux for 100 h gave the reaction mixture, which was diluted with 50 mL of EtOH and 50 mL of 2 N HCl, the product was filtered off, and purified by EtOAc extraction to give the invented complex [(LB1)3Ir] (1a) with 49% yield. The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

The Article related to iridium cyclometalated arylpyridine arylquinoline arylisoquinoline arylbenzimidazole complex preparation electroluminescence, electroluminescent material iridium cyclometalated complex preparation luminescence oled manufacturing, bromination borylation suzuki buchwald coupling derivatization iridium cyclometalated complex and other aspects.Recommanded Product: 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Davies, David L. et al. published their research in Dalton Transactions in 2004 |CAS: 109660-12-0

The Article related to pyridyloxazoline cyclopentadienyl rhodium chloride preparation hydrolysis ligand substitution, crystal structure cyclopentadienyl pyridyloxazoline rhodium chloride, mol structure cyclopentadienyl pyridyloxazoline rhodium chloride, methacrolein diels alder reaction cyclopentadiene catalyst pyridyloxazoline rhodium chloride and other aspects.Product Details of 109660-12-0

Davies, David L.; Fawcett, John; Garratt, Shaun A.; Russell, David R. published an article in 2004, the title of the article was Cp*Rh complexes with pyridyloxazolines: synthesis, fluxionality and applications as asymmetric catalysts for Diels-Alder reactions.Product Details of 109660-12-0 And the article contains the following content:

Half-sandwich complexes [RhCl(pymox)Cp*][SbF6] (1-7) (pymox = pyridyloxazoline) were synthesized as single diastereomers. Treatment of these with AgSbF6 generates dications [Rh(OH2)(pymox)Cp*]2+ which are fluxional at room temperature and which are enantioselective catalysts for the Diels-Alder reaction of methacrolein and cyclopentadiene. Treatment of the dication [Rh(OH2)(iPr-pymox)Cp*]2+ with [X]- gives [RhX(iPr-pymox)Cp*][SbF6] (X = Br, I) as single diastereomers while reaction with 4-Mepy (4-methylpyridine) gives [Rh(4-Mepy)(iPr-pymox)Cp*][SbF6] as a mixture of diastereomers. Two complexes, [RhCl(iPr-pymox)Cp*][SbF6] (3) and [RhCl(Bz-pymox)Cp*][SbF6] (6) were characterized by x-ray crystallog. The experimental process involved the reaction of 2-(4,5-Dihydro-4,4-dimethyl-2-oxazolyl)pyridine(cas: 109660-12-0).Product Details of 109660-12-0

The Article related to pyridyloxazoline cyclopentadienyl rhodium chloride preparation hydrolysis ligand substitution, crystal structure cyclopentadienyl pyridyloxazoline rhodium chloride, mol structure cyclopentadienyl pyridyloxazoline rhodium chloride, methacrolein diels alder reaction cyclopentadiene catalyst pyridyloxazoline rhodium chloride and other aspects.Product Details of 109660-12-0

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Ankersen, Michael et al. published their patent in 1998 |CAS: 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

On December 30, 1998, Ankersen, Michael; Stidsen, Carsten Enggaard; Crider, Michael Albert published a patent.Application of 199522-66-2 The title of the patent was Preparation of thioureas as somatostatin agonists and antagonists for treating diseases related to the eye. And the patent contained the following:

The title compounds [I; m = 2-6; n = 1-3; p = 1-6; R1, R2 = H, (un)substituted C1-6 alkyl; X = S, O, NH, NCOPh, N(CN); A, B, D = (un)substituted aryl, heteroaryl], somatostatin receptor ligands of nonpeptide origin which have high and/or selective affinity to the somatostatin receptor protein designated SSTR4 (no data), and are useful for the treatment of a disease associated with an adverse condition in the retina and/or iris-ciliary body of a mammal such as high intraocular pressure (IOP) and/or deep ocular infections, were prepared and formulated. The diseases which may be treated with compounds I are e.g. glaucoma, stromal keratitis, iritis, retinitis, cataract and conjunctivitis. Compounds I are effective at 0.001-50 mg/kg/day. E.g., a 5-step synthesis of II.2HCl, starting with propane-1,3-diamine and 2-bromopyridine, is described. The experimental process involved the reaction of N1-(5-Bromopyrid-2-yl)ethane-1,2-diamine(cas: 199522-66-2).Application of 199522-66-2

The Article related to thiourea preparation formulation somatostatin agonist antagonist, glaucoma thiourea preparation formulation, eye disease thiourea preparation formulation, keratitis thiourea preparation formulation, iritis thiourea preparation formulation, retinitis thiourea preparation formulation, cataract thiourea preparation formulation and other aspects.Application of 199522-66-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Sutton, Cara E. et al. published their research in Chemistry – A European Journal in 2012 |CAS: 75449-26-2

The Article related to preparation macrocyclic bipyridine tetraazacrown ligand copper chloro complex, solution speciation macrocyclic bipyridine tetraazacrown ligand copper chloro complex, allosterism copper complexation macrocyclic bipyridine tetraazacrown ligand, crystal structure copper chloro macrocyclic bipyridine tetraazacrown ligand complex and other aspects.Quality Control of [2,2′-Bipyridine]-3,3′-diamine

Sutton, Cara E.; Harding, Lindsay P.; Hardie, Michaele; Riis-Johannessen, Thomas; Rice, Craig R. published an article in 2012, the title of the article was Allosteric Effects in a Ditopic Ligand Containing Bipyridine and Tetra-aza-crown Donor Units.Quality Control of [2,2′-Bipyridine]-3,3′-diamine And the article contains the following content:

The authors report the synthesis and coordination properties of a macrocyclic ligand containing bipyridine and tetraazacrown N-donor units. Both sites complex Cu(II), but the donor mode of tetraazacrown unit is controlled by the binding state of the bipyridine unit. An allosteric effect, characterized by neg. cooperative binding of a second Cu(II), is assigned to the tetraazacrown being able to coordinate through only three of its N-donors when the bipyridine site is occupied. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).Quality Control of [2,2′-Bipyridine]-3,3′-diamine

The Article related to preparation macrocyclic bipyridine tetraazacrown ligand copper chloro complex, solution speciation macrocyclic bipyridine tetraazacrown ligand copper chloro complex, allosterism copper complexation macrocyclic bipyridine tetraazacrown ligand, crystal structure copper chloro macrocyclic bipyridine tetraazacrown ligand complex and other aspects.Quality Control of [2,2′-Bipyridine]-3,3′-diamine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Thongpaen, Jompol et al. published their research in Angewandte Chemie, International Edition in 2019 |CAS: 1349171-28-3

The Article related to rhodium imidazolylidenecarboxylate carbene complex preparation catalyst borylation arene, crystal structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, mol structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, carbon hydrogen activation kinetics borylation arylpyridine rhodium carbene catalyst and other aspects.Recommanded Product: 1349171-28-3

Thongpaen, Jompol; Manguin, Romane; Dorcet, Vincent; Vives, Thomas; Duhayon, Carine; Mauduit, Marc; Basle, Olivier published an article in 2019, the title of the article was Visible Light Induced Rhodium(I)-Catalyzed C-H Borylation.Recommanded Product: 1349171-28-3 And the article contains the following content:

An efficient visible light induced Rh(I)-catalyzed regioselective borylation of aromatic C-H bonds is reported. The photocatalytic system is based on a single NHC-Rh(I) complex capable of both harvesting visible light and enabling the bond breaking/forming at room temperature The chelating nature of the NHC-carboxylate ligand was critical to ensure the stability of the Rh(I) complex and to provide excellent photocatalytic activities. Exptl. mechanistic studies evidenced a photooxidative ortho C-H bond addition upon irradiation with blue LEDs, leading to a cyclometalated Rh(III)-hydride intermediate. The experimental process involved the reaction of 2-(2-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)pyridine(cas: 1349171-28-3).Recommanded Product: 1349171-28-3

The Article related to rhodium imidazolylidenecarboxylate carbene complex preparation catalyst borylation arene, crystal structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, mol structure pyridylphenyl rhodium imidazolylidenecarboxylate carbene complex, carbon hydrogen activation kinetics borylation arylpyridine rhodium carbene catalyst and other aspects.Recommanded Product: 1349171-28-3

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Maronna, Astrid et al. published their research in Chemistry – A European Journal in 2013 |CAS: 75449-26-2

The Article related to bisguanidine biphenyl binaphthyl bipyridyl backbone protonation proton sponge, crystal structure protonated biaryl bisguanidine group 10 metal complex, dft optimized geometry protonated biaryl bisguanidine, fluorescence bipyridyl bisguanidine, heck catalyst palladium bipyridyl bisguanidine allyl complex, spin density nickel biaryl bisguanidine and other aspects.SDS of cas: 75449-26-2

Maronna, Astrid; Huebner, Olaf; Enders, Markus; Kaifer, Elisabeth; Himmel, Hans-Joerg published an article in 2013, the title of the article was Bisguanidines with Biphenyl, Binaphthyl, and Bipyridyl Cores: Proton-Sponge Properties and Coordination Chemistry.SDS of cas: 75449-26-2 And the article contains the following content:

Herein, the authors report on the synthesis, protonation, and coordination chem. of chelating guanidine ligands with biphenyl, binaphthyl, and bipyridyl backbones. The ligands are proton sponges, and this protonation was studied exptl. and by using quantum-chem. calculations Group 10 metal (Ni, Pd, and Pt) complexes with different metal/ligand ratios were synthesized. In the case of the bipyridyl systems, coordination occurs exclusively at the pyridine N atoms, as opposed to protonation. The spin-d. distribution and the magnetism were evaluated for paramagnetic NiII complexes with the aid of paramagnetic NMR spectroscopic studies in alliance with quantum-chem. calculations and magnetic (SQUID) measurements. Through direct delocalization from the singly occupied MOs (SOMOs), a significant amount of spin d. is placed on the guanidinyl groups, and spin polarization also transports spin d. onto the aromatic backbone. The experimental process involved the reaction of [2,2′-Bipyridine]-3,3′-diamine(cas: 75449-26-2).SDS of cas: 75449-26-2

The Article related to bisguanidine biphenyl binaphthyl bipyridyl backbone protonation proton sponge, crystal structure protonated biaryl bisguanidine group 10 metal complex, dft optimized geometry protonated biaryl bisguanidine, fluorescence bipyridyl bisguanidine, heck catalyst palladium bipyridyl bisguanidine allyl complex, spin density nickel biaryl bisguanidine and other aspects.SDS of cas: 75449-26-2

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem

Stoessel, Philipp et al. published their patent in 2015 |CAS: 39919-70-5

The Article related to nitrogen heterocyclic compound preparation povarov cyclization cycloalkene aldehyde amine, heterocyclic polycyclic aromatic nitrogen preparation component organic electronic device, organic semiconductor nitrogen heterocycle host hole electron transporter, metallacyclic complex iridium platinum nitrogen heterocycle preparation electroluminescence and other aspects.Reference of 6-(tert-Butyl)pyridin-3-amine

On January 8, 2015, Stoessel, Philipp; Joosten, Dominik; Koenen, Nils published a patent.Reference of 6-(tert-Butyl)pyridin-3-amine The title of the patent was Polycyclic nitrogen heterocyclic compounds as semiconducting materials for components of organic electronic devices. And the patent contained the following:

Polycyclic nitrogen heterocycles I (1, X = methyne, N; E = bivalent group, forming 5- or 6-membered condensed ring; Y = O, S, 1,2-ethenediyl, imino, borylene, silylene CO, alkenylidene, SO, SO2, 1,2-ethanediyl, phosphinidene, phosphinylidene; R = H, D, halo, amino, CN, NO2, OH, CO2H, carbamoyl, silyl, boryl, acyl, phosphinyl, sulfinyl, sulfonyl, sulfo, C1-20 alkyl, alkoxy, alkylthio, alkenyl, alkynyl; R1 = R or R1-R1 = bond) and their cyclometalated platinum and iridium complexes [M(L)n(L1)m] (2, M = Ir, Pd, Pt, Os, Re; L1 = auxiliary ligand), useful as organic semiconducting materials for manufacturing of charge-transporting and charge-injecting layers in organic semiconductor devices, preferably, in organic light-emitting devices (OLEDs) and featuring glass transition temperature at least 110°, were prepared by heterocyclization of aromatic aldehydes with aromatic amines and alkenes with optional subsequent cyclometalation and complexation with protonated ligands HpL1. In an example, Povarov reaction of 500 mmol of aniline with 550 mmol of benzaldehyde and 1 mol of norbornene in 1300 mL of CH2Cl2 catalyzed with 100 mmol of BF3·OEt2 for 40 h at reflux with subsequent oxidation by 5 mol of MnO2 for 16 h at reflux in 1000 mL of 1,2-dichlorobenzene under water separation gave the invented compound (1a, shown as I, E = CH:CHCH:CH, X = CH, Y = CH2, R = R1 = H) with 56% yield. The present invention relates to compounds having polycyclic structural units and to electronic devices, in particular organic electroluminescent devices, containing said compounds The experimental process involved the reaction of 6-(tert-Butyl)pyridin-3-amine(cas: 39919-70-5).Reference of 6-(tert-Butyl)pyridin-3-amine

The Article related to nitrogen heterocyclic compound preparation povarov cyclization cycloalkene aldehyde amine, heterocyclic polycyclic aromatic nitrogen preparation component organic electronic device, organic semiconductor nitrogen heterocycle host hole electron transporter, metallacyclic complex iridium platinum nitrogen heterocycle preparation electroluminescence and other aspects.Reference of 6-(tert-Butyl)pyridin-3-amine

Referemce:
Pyridine – Wikipedia,
Pyridine | C5H5N – PubChem